id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
ijcto-411	Patel, Shyamal; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York; Mourad, Waleed; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York; Patel, Rajal; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York; Kabarriti, Rafi; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York; Young, Rebekah; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York; Yaparpalvi, Ravi; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York; Hong, Linda; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York; LaSala, Patrick; Department of Neurosurgery, Montefiore Medical Center, Bronx, New York; Guha, Chandan; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York; Kalnicki, Shalom; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York; Garg, Madhur; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York	The role of pre- and post-SRS systemic therapy in patients with NSCLC brain metastases	2015-12-07	8	.pdf	application/pdf	4714	254	43	Our results also suggest that delaying theinitiation of systemic therapy after SRS to >30 days maypotentially improve survival, even in patients withsynchronous metastases. ISSN 2330-4049 The use of systemic therapy (chemotherapy or targetedtherapies) in patients with brain metastases from lungcancer has also been examined.8,13	cache/ijcto-411.pdf	txt/ijcto-411.txt
